Agenus Inc
$ 4.79
3.23%
17 Apr - close price
- Market Cap 183,928,000 USD
- Current Price $ 4.79
- High / Low $ 4.80 / 4.52
- Stock P/E N/A
- Book Value -7.68
- EPS N/A
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -12.79 %
- 52 Week High 7.34
- 52 Week Low 1.96
About
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in Lexington, Massachusetts.
Analyst Target Price
$15.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-16 | 2025-11-10 | 2025-08-11 | 2025-05-05 | 2025-03-12 | 2024-11-05 | 2024-08-08 | 2024-05-07 | 2024-03-14 | 2023-11-07 | 2023-08-08 | 2023-05-09 |
| Reported EPS | 0.6808 | 1.94 | -1 | -1.03 | -2.04 | -3.08 | -2.52 | -3.04 | -0.13 | -0.16 | -0.2 | -0.22 |
| Estimated EPS | -1.3 | -0.28 | -0.27 | -1.98 | -2.542 | -2.33 | -1.44 | -3.22 | -0.05 | -0.19 | -0.2 | -0.21 |
| Surprise | 1.9808 | 2.22 | -0.73 | 0.95 | 0.502 | -0.75 | -1.08 | 0.18 | -0.08 | 0.03 | 0 | -0.01 |
| Surprise Percentage | 152.3692% | 792.8571% | -270.3704% | 47.9798% | 19.7482% | -32.1888% | -75% | 5.5901% | -160% | 15.7895% | 0% | -4.7619% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.95 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AGEN
2026-04-18 02:10:11
Agenus announced positive Phase II data for its combination therapy of botensilimab, balstilimab, and agenT-797 in PD-1 refractory gastroesophageal cancer. The study showed a 77% disease control rate and durable survival beyond 20 months in a subset of patients, with the induction arm demonstrating significant improvements in progression-free survival (6.9 vs. 3.5 months) and overall survival (9.5 vs. 5.2 months). Correlative analyses indicated immune reprogramming, including increased T cell and dendritic cell infiltration, supporting the observed clinical benefits.
2026-04-17 21:09:48
Agenus Inc. released Phase II data showing that a combination of botensilimab (BOT), balstilimab (BAL), and agenT-797 resulted in a 77% disease control rate and long-term survival in PD-1 refractory gastroesophageal cancer patients. An induction strategy using these drugs significantly improved progression-free survival and overall survival, with 43% of induction-treated patients alive at 12 and 18 months. These findings, presented at AACR, suggest immune reprogramming and durable benefits in a heavily pretreated population.
2026-04-17 02:08:52
Agenus has released its updated April 2026 corporate overview, detailing the progress of its BOT+BAL program in MSS colorectal cancer. The overview covers clinical development, registration momentum, expansion opportunities, and the company's financial and manufacturing strength. Key highlights include the rationale for the Phase 3 BATTMAN study in R/R MSS mCRC and durable survival data supporting the program.
2026-04-13 20:38:53
Thomas L. Harrison, a director at AGENUS INC (AGEN), was granted 9,228 shares of common stock as board fees. This transaction, valued at an average price of $3.319 per share, was conducted under the company’s Board Compensation Election Policy, allowing directors to receive fees in stock instead of cash. Following this award, Harrison directly holds a total of 38,998 common shares in AGENUS INC.
2026-04-06 20:14:52
Agenus director Garo H. Armen reported receiving 4,629 shares of common stock as fully vested compensation in lieu of cash salary for the pay period ending April 3, 2026. The shares were valued at $3.33 each, based on the closing price on April 2, 2026. Following this transaction, Mr. Armen directly holds 339,147 shares of Agenus common stock and also has indirect holdings through IRA accounts, a GRAT, and a partnership.
2026-04-06 00:11:11
Agenus will present new Phase II data on its botensilimab + balstilimab (BOT/BAL) combination with MiNK Therapeutics' agenT-797 iNKT cell therapy for PD-1 refractory gastroesophageal cancer at the AACR 2026 Annual Meeting. The presentation will occur on April 20, 2026, from 2:00–5:00 PM PT / 5:00–8:00 PM ET in Poster Section 52, abstract CT166. This study is an investigator-initiated trial.
